Advances in the Management of Malignant Mesothelioma

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2003 Jun 5

PMID 12781077

Citations 1

Authors

Mazen Y Khalil

Marissa Mapa

Hyung Ju C Shin

Dong M Shin

Affiliations

Soon will be listed here.

Abstract

Malignant mesotheliomas are very aggressive tumors that originate from mesothelial cells, which form the serosal lining of the pleura, pericardial, and peritoneal cavities. Finding effective chemotherapeutic treatment for malignant mesothelioma is a challenge. There is no standard treatment because this tumor is relatively resistant to therapy. A resurgence of interest has been expressed in novel therapies and conventional treatments used in different ways. Several treatment modalities have been studied, including chemotherapy, radiotherapy, surgery, and immunotherapy. Chemotherapy can be administered systemically or directly into the pleura. This review presents the results of the most recent trials and highlights the most promising advances in the battle against this aggressive disease.

Citing Articles

Electrolyte and Fluid Transport in Mesothelial Cells.

Ji H, Nie H J Epithel Biol Pharmacol. 2009; 1:1-7.

PMID: 19169368 PMC: 2629602. DOI: 10.2174/1875044300801010001.

References

Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A . Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000; 36(12):1514-21. DOI: 10.1016/s0959-8049(00)00139-8. View

Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M . A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994; 12(6):1156-63. DOI: 10.1200/JCO.1994.12.6.1156. View

Sugarbaker D, Flores R, Jaklitsch M, Richards W, Strauss G, Corson J . Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1998; 117(1):54-63; discussion 63-5. DOI: 10.1016/s0022-5223(99)70469-1. View

Hagemeijer A, Versnel M, van Drunen E, Moret M, Bouts M, van der Kwast T . Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990; 47(1):1-28. DOI: 10.1016/0165-4608(90)90258-c. View

Buchdunger E, Cioffi C, Law N, Stover D, Druker B, Lydon N . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295(1):139-45. View

STEELE J, Shamash J, Evans M, Gower N, Tischkowitz M, Rudd R . Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18(23):3912-7. DOI: 10.1200/JCO.2000.18.23.3912. View

Carbone M, Fisher S, Powers A, Pass H, Rizzo P . New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol. 1999; 180(2):167-72. DOI: 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q. View

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G . Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-75. DOI: 10.1002/path.824. View

Procopio A, Strizzi L, Vianale G, Betta P, Puntoni R, Fontana V . Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer. 2000; 29(2):173-9. DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1019>3.0.co;2-b. View

10.

van Haarst J, Baas P, Manegold C, Schouwink J, Burgers J, de Bruin H . Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86(3):342-5. PMC: 2375227. DOI: 10.1038/sj.bjc.6600118. View

11.

Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A . Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol. 2002; 197(2):218-23. DOI: 10.1002/path.1125. View

12.

Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A . Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol. 2001; 18(5):1093-8. DOI: 10.3892/ijo.18.5.1093. View

13.

Henderson D, Shilkin K, Whitaker D . Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol. 1998; 110(3):397-404. DOI: 10.1093/ajcp/110.3.397. View

14.

Boutin C, Rey F, Viallat J . Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995; 108(3):754-8. DOI: 10.1378/chest.108.3.754. View

15.

Gordon Jr W, Antman K, Greenberger J, Weichselbaum R, Chaffey J . Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys. 1982; 8(1):19-25. DOI: 10.1016/0360-3016(82)90379-0. View

16.

Pass H, Temeck B, Kranda K, Steinberg S, Feuerstein I . Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998; 115(2):310-7; discussion 317-8. DOI: 10.1016/S0022-5223(98)70274-0. View

17.

Ryan C, Herndon J, Vogelzang N . A review of chemotherapy trials for malignant mesothelioma. Chest. 1998; 113(1 Suppl):66S-73S. DOI: 10.1378/chest.113.1_supplement.66s. View

18.

Kindler H, Belani C, Herndon 2nd J, Vogelzang N, Suzuki Y, Green M . Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999; 86(10):1985-91. View

19.

Byrne M, Davidson J, Musk A, Dewar J, Van Hazel G, Buck M . Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999; 17(1):25-30. DOI: 10.1200/JCO.1999.17.1.25. View

20.

Thodtmann R, Depenbrock H, Dumez H, Blatter J, Johnson R, van Oosterom A . Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999; 17(10):3009-16. DOI: 10.1200/JCO.1999.17.10.3009. View